Drug profile

The FDA adverse-event record for Bone And Joint Support

62 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bone And Joint Support. See the species affected, top reactions, and outcomes below.

62
adverse-event reports
8.1%
death-coded share
Dog
most-reported species
14
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
62
Total Reports
5
Deaths Reported
8.1%
Death Rate

Active Ingredients

Bone And Joint Support

Administration Routes

OralUnknownIntramuscular

Species Affected

Dog 57
Cat 4
Human 1

Most Affected Breeds

Retriever - Labrador 12
Retriever - Golden 4
Boxer (German Boxer) 3
Shepherd Dog - Australian 3
Shepherd Dog - German 3
Domestic Shorthair 3
Chihuahua 2
Collie - Border 2
Spitz - German Pomeranian 2
Pinscher - Miniature 2

Most Reported Reactions

Vomiting 14
Diarrhoea 7
Other abnormal test result NOS 5
Emesis 5
Death by euthanasia 5
Anaemia NOS 5
Lack of efficacy - NOS 4
Abnormal radiograph finding 4
Elevated blood urea nitrogen (BUN) 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Bone and joint disorder NOS 3
Seizure NOS 3

Outcome Breakdown

Outcome Unknown
22 (35.5%)
Ongoing
19 (30.6%)
Recovered/Normal
15 (24.2%)
Euthanized
5 (8.1%)
Recovered with Sequela
1 (1.6%)

Bone And Joint Support Adverse Event Insights

62 reports name Bone And Joint Support; 5 recorded a death outcome (8.1% of reported events, not a population-level mortality rate). Active ingredient: Bone And Joint Support. Administration routes: Oral, Unknown, Intramuscular.

By species: Dog (57 reports), Cat (4 reports), Human (1 reports). By breed: Retriever - Labrador (12), Retriever - Golden (4), Boxer (German Boxer) (3).

Leading clinical signs: Vomiting (14), Diarrhoea (7), Other abnormal test result NOS (5), Emesis (5). Outcome, 62 coded reports: Outcome Unknown leads at 35.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.